Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well imatinib mesylate works in treating patients with
gastrointestinal stromal tumor that was completely removed during surgery. Imatinib mesylate
may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth